CD274 and non-small cell lung carcinoma: We optimized the staining of PD-L1 using a control TMA of NSCLC and determined that the RADD protocol could be multiplexed with the PD-L1 antibody to allow co-staining of oxidative DNA damage and PD-L1 expression (Figure 4 and Figure 5).